Project Grant HT94252310974
Award Date 9/30/23
Completion Date 9/29/26
Dollars Obligated $653K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
- The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $172,374 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of fatty acid metabolism in chromophobe renal cell carcinoma. The award was obligated on August 1, 2025, with an ultimate completion date of September 29, 2026, following a modification to the original...
- The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
- Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
- The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
- This $1,428,720.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Brigham & Women's Hospital Inc. to investigate the degradation of the menin/KMT2A protein complex for the treatment of myeloid neoplasms. The 4-year project, running from August 1, 2025 to July 31, 2029, aims to advance scientific understanding and develop potential new therapeutic approaches for these blood cancers. As a...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...